ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026
Development and validation of MRI-based radiomics models for predicting recurrence in patients with spine and pelvis chordomas.
Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSpine and pelvis chordoma (SPC) is a rare and aggressive mesenchymal tumor with poor long-term recurrence-free survival rates. Accurate preoperative prediction of recurrence remains a significant clinical challenge, and reliable prognostic methods are lacking. PURPOSE: To develop and validate MRI-based radiomics models for predicting recurrence in SPC. STUDY
designA single-center retrospective study. PATIENT SAMPLE: A total of 135 SPC patients who underwent preoperative MRI, including T2-weighted imaging (T2WI) and contrast-enhanced T1-weighted (CET1) sequences. OUTCOME MEASURES: Recurrence status of SPC, evaluated using accuracy (ACC), sensitivity (SEN), specificity (SPE), area under the receiver operating characteristic curve (AUC), positive predictive value (PPV), and negative predictive value (NPV).
methodsA total of 2394 radiomic features were extracted from manually segmented MRI regions of interest. Features were selected using Spearman correlation analysis and LASSO regression with ten-fold cross-validation. Eleven machine learning algorithms were applied to construct radiomics models, and clinical predictors were identified via univariate and multivariate logistic regression. A combined model incorporating radiomics and clinical data was developed and visualized with a nomogram. Model performance was evaluated using ROC curves, decision curve analysis (DCA), calibration plots, and the DeLong test.
resultsAge, tumor size, and resection mode were identified as independent prognostic factors. Among radiomics-based models, the Random Forest (RF) model showed the best performance, with AUCs of 0.929 and 0.847 in the training and test cohorts, respectively, outperforming the clinical model with AUCs of 0.680 and 0.700. The combined model integrating radiomics and clinical features further improved performance, with AUCs of 0.945 and 0.897, and demonstrated the highest net clinical benefit according to DCA.
conclusionsThe integrated model constructed by radiomics and clinical characteristics achieved robust preoperative recurrence prediction for SPC, offering personalized treatment and enhanced clinical decision-making.
Indexed as
Identifiers
42752977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.